Viking Therapeutics (VKTX) announced the initiation of a Phase 2 clinical trial of the oral tablet formulation of VK2735, the company’s dual agonist of the glucagon-like peptide 1 and glucose-dependent insulinotropic polypeptide receptors. VK2375 is being developed in both oral and subcutaneous formulations for the potential treatment of various metabolic disorders such as obesity.
Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on VKTX:
- Unusually active option classes on open January 6th
- Opco lists five potential biotech targets into JPMorgan conference
- Biotech Alert: Searches spiking for these stocks today
- Viking gains ground as Novo Nordisk stumbles, says H.C. Wainwright
- BTIG reiterates Buy on Viking Therapeutics after Novo’s CagriSema ‘underwhelms’
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
